The association of triglyceride-glucose-waist circumference with metabolic associated fatty liver disease and the severity of liver steatosis and fibrosis in American adults: a population-based study

References

• Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; Apr 177(4):1335–1347. doi: 10.1097/hep.0000000000000004.
   PubMed Web of Science ®Google Scholar
• Hardy T, Oakley F, Anstee QM, et al. Nonalcoholic fatty liver disease: Pathogenesis and disease spectrum. Annu Rev Pathol. 2016; May 2311(1):451–496. doi: 10.1146/annurev-pathol-012615-044224.
   PubMedGoogle Scholar
• Manne V, Handa P, Kowdley KV. Pathophysiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Clin Liver Dis. 2018; Feb22(1):23–37. doi: 10.1016/j.cld.2017.08.007.
   PubMed Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020; Jul73(1):202–209. doi: 10.1016/j.jhep.2020.03.039.
   PubMed Web of Science ®Google Scholar
• Yilmaz Y. The heated debate over NAFLD renaming: an ongoing Saga. Hepatol Forum. 2023;4(3):89–91. doi: 10.14744/hf.2023.2023.0044.
   PubMedGoogle Scholar
• Lin S, Huang J, Wang M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020; Sep40(9):2082–2089. doi: 10.1111/liv.14548.
   PubMed Web of Science ®Google Scholar
• Huang Q, Zou X, Wen X, et al. NAFLD or MAFLD: which has closer association with all-cause and cause-specific mortality?-results from NHANES III. Front Med (Lausanne). 2021;8:693507. doi: 10.3389/fmed.2021.693507.
   PubMedGoogle Scholar
• Yamamura S, Eslam M, Kawaguchi T, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020; Dec40(12):3018–3030. doi: 10.1111/liv.14675.
   PubMed Web of Science ®Google Scholar
• Gill MG, Majumdar A. Metabolic associated fatty liver disease: addressing a new era in liver transplantation. World J Hepatol. 2020; Dec 2712(12):1168–1181. doi: 10.4254/wjh.v12.i12.1168.
   PubMed Web of Science ®Google Scholar
• Shiha G, Korenjak M, Eskridge W, et al. Redefining fatty liver disease: an international patient perspective. Lancet Gastroenterol Hepatol. 2021; Jan6(1):73–79. doi: 10.1016/s2468-1253(20)30294-6.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with cardiovascular diseases. Int J Mol Sci. 2021; Oct 2722(21):11629. doi: 10.3390/ijms222111629.
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Kubota N, Yamauchi T, et al. Role of insulin resistance in MAFLD. Int J Mol Sci. 2021; Apr 1622(8):4156. doi: 10.3390/ijms22084156.
   PubMed Web of Science ®Google Scholar
• Demirtas CO, Sapmaz A, Gurel BA, et al. The clinical and histological characteristics of patients with biopsy-proven non-alcoholic fatty liver disease in the absence of insulin resistance. Hepatol Forum. 2020; Sep1(3):101–108. doi: 10.14744/hf.2020.2020.0018.
   PubMedGoogle Scholar
• Li R, Li Q, Cui M, et al. Clinical surrogate markers for predicting metabolic syndrome in Middle-aged and elderly chinese. J Diabetes Investig. 2018; Mar9(2):411–418. doi: 10.1111/jdi.12708.
   PubMed Web of Science ®Google Scholar
• Sánchez-García A, Rodríguez-Gutiérrez R, Mancillas-Adame L, et al. Diagnostic accuracy of the triglyceride and glucose index for insulin resistance: a systematic review. Int J Endocrinol. 2020;2020:4678526–4678527. doi: 10.1155/2020/4678526.
   PubMed Web of Science ®Google Scholar
• Taheri E, Pourhoseingholi MA, Moslem A, et al. The triglyceride-glucose index as a clinical useful marker for metabolic associated fatty liver disease (MAFLD): a population-based study among iranian adults. J Diabetes Metab Disord. 2022; Jun21(1):97–107. doi: 10.1007/s40200-021-00941-w.
   PubMed Web of Science ®Google Scholar
• Beran A, Ayesh H, Mhanna M, et al. Triglyceride-Glucose index for early prediction of nonalcoholic fatty liver disease: a Meta-Analysis of 121,975 individuals. J Clin Med. 2022; May 911(9):2666. doi: 10.3390/jcm11092666.
   PubMed Web of Science ®Google Scholar
• Zheng S, Shi S, Ren X, et al. Triglyceride glucose-waist circumference, a novel and effective predictor of diabetes in first-degree relatives of type 2 diabetes patients: cross-sectional and prospective cohort study. J Transl Med. 2016; Sep 714(1):260. doi: 10.1186/s12967-016-1020-8.
   PubMedGoogle Scholar
• Lim J, Kim J, Koo SH, et al. Comparison of triglyceride glucose index, and related parameters to predict insulin resistance in korean adults: an analysis of the 2007-2010 korean national health and nutrition examination survey. PLoS One. 2019;14(3):e0212963. doi: 10.1371/journal.pone.0212963.
   PubMed Web of Science ®Google Scholar
• Kim HS, Cho YK, Kim EH, et al. Triglyceride glucose-waist circumference is superior to the homeostasis model assessment of insulin resistance in identifying nonalcoholic fatty liver disease in healthy subjects. J Clin Med. 2021; Dec 2311(1):41. PubMed PMID: 35011784; PubMed Central PMCID: PMCPMC8745545. eng. doi: 10.3390/jcm11010041.
   PubMed Web of Science ®Google Scholar
• Malek M, Khamseh ME, Chehrehgosha H, et al. Triglyceride glucose-waist to height ratio: a novel and effective marker for identifying hepatic steatosis in individuals with type 2 diabetes mellitus. Endocrine. 2021; Dec74(3):538–545. PubMed PMID: 34355342; eng. doi: 10.1007/s12020-021-02815-w.
   PubMed Web of Science ®Google Scholar
• Zipf G, Chiappa M, Porter KS, et al. National health and nutrition examination survey: plan and operations, 1999-2010. Vital Health Stat 1. 2013; Ser. 1, Aug(56):1–37. PubMed PMID: 25078429; eng.
   PubMedGoogle Scholar
• Chowdhury AB, Mehta KJ. Liver biopsy for assessment of chronic liver diseases: a synopsis. Clin Exp Med. 2022;23Feb 22. (2):273–285. doi: 10.1007/s10238-022-00799-z.
   PubMed Web of Science ®Google Scholar
• Aykut UE, Akyuz U, Yesil A, et al. A comparison of FibroMeter™ NAFLD score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease. Scand J Gastroenterol. 2014; Nov49(11):1343–1348. doi: 10.3109/00365521.2014.958099.
   PubMed Web of Science ®Google Scholar
• Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019; Apr156(5):1264–1281.e4. PubMed PMID: 30660725; doi: 10.1053/j.gastro.2018.12.036.
   PubMed Web of Science ®Google Scholar
• Kim D, Konyn P, Cholankeril G, et al. Physical activity is associated with nonalcoholic fatty liver disease and significant fibrosis measured by FibroScan. Clin Gastroenterol Hepatol. 2022; Jun20(6):e1438–e1455. doi: 10.1016/j.cgh.2021.06.029.
   PubMed Web of Science ®Google Scholar
• Ciardullo S, Perseghin G. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes. Metabolism. 2021; Aug121:154752. doi: 10.1016/j.metabol.2021.154752.
   PubMed Web of Science ®Google Scholar
• Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019; May156(6):1717–1730. doi: 10.1053/j.gastro.2019.01.042.
   PubMed Web of Science ®Google Scholar
• Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017; May66(5):1022–1030.doi: 10.1016/j.jhep.2016.12.022.
   PubMed Web of Science ®Google Scholar
• Weng Z, Ou W, Huang J, et al. Circadian misalignment rather than sleep duration is associated with MAFLD: a population-based propensity Score-Matched study. Nat Sci Sleep. 2021;13:103–111. doi: 10.2147/nss.s290465.
   PubMed Web of Science ®Google Scholar
• Sharma S, Fleming SE. Use of HbA(1C) testing to diagnose pre-diabetes in high risk african American children: a comparison with fasting glucose and HOMA-IR. Diabetes Metab Syndr. 2012; Jul-Sep6(3):157–162. doi: 10.1016/j.dsx.2012.09.004.
   PubMedGoogle Scholar
• Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016; Jul22 Suppl 3(Suppl 3):1–203. doi: 10.4158/ep161365.gl.
   PubMedGoogle Scholar
• Wang L, Li X, Wang Z, et al. Trends in prevalence of diabetes and control of risk factors in diabetes among US adults, 1999-2018. Jama. 2021; Jun 25326(8):1–13. doi: 10.1001/jama.2021.9883.
   PubMed Web of Science ®Google Scholar
• Rattan P, Penrice DD, Ahn JC, et al. Inverse association of telomere length with liver disease and mortality in the US population. Hepatol Commun. 2022; Feb6(2):399–410. doi: 10.1002/hep4.1803.
   PubMed Web of Science ®Google Scholar
• Fowler JR, Tucker LA, Bailey BW, et al. Physical activity and insulin resistance in 6,500 NHANES adults: the role of abdominal obesity. J Obes. 2020;2020:3848256–3848210. doi: 10.1155/2020/3848256.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhou M, Yan H, et al. Association of serum total 25-hydroxy-vitamin D concentration and risk of all-cause, cardiovascular and malignancies-specific mortality in patients with hyperlipidemia in the United States. Front Nutr. 2022;9:971720. PubMed PMID: 36337630; doi: 10.3389/fnut.2022.971720.
   PubMed Web of Science ®Google Scholar
• Zhang S, Du T, Zhang J, et al. The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. Lipids Health Dis. 2017; Jan 1916(1):15. PubMed PMID: 28103934; doi: 10.1186/s12944-017-0409-6.
   PubMedGoogle Scholar
• Ramdas Nayak VK, Satheesh P, Shenoy MT, et al. Triglyceride glucose (TyG) index: a surrogate biomarker of insulin resistance. J Pak Med Assoc. 2022; May72(5):986–988. doi: 10.47391/jpma.22-63.
   PubMed Web of Science ®Google Scholar
• Song S, Son DH, Baik SJ, et al. Triglyceride glucose-waist circumference (TyG-WC) is a reliable marker to predict non-Alcoholic fatty liver disease. Biomedicines. 2022; Sep 1110(9):2251. PubMed PMID: 36140352; doi: 10.3390/biomedicines10092251.
   PubMed Web of Science ®Google Scholar
• Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020;12(1):60. doi: 10.1186/s13098-020-00570-y.
   PubMed Web of Science ®Google Scholar
• Xue Y, Xu J, Li M, et al. Potential screening indicators for early diagnosis of NAFLD/MAFLD and liver fibrosis: triglyceride glucose index-related parameters. Front Endocrinol (Lausanne). 2022;13:951689. doi: 10.3389/fendo.2022.951689.
   PubMed Web of Science ®Google Scholar
• Kwon YM, Oh SW, Hwang SS, et al. Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in korean adults. Am J Gastroenterol. 2012; Dec107(12):1852–1858. doi: 10.1038/ajg.2012.314.
   PubMed Web of Science ®Google Scholar
• Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in asia. J Hepatol. 2017; Oct67(4):862–873. PubMed PMID: 28642059; eng. doi: 10.1016/j.jhep.2017.06.003.
   PubMed Web of Science ®Google Scholar
• Raimi TH, Dele-Ojo BF, Dada SA, et al. Triglyceride-Glucose index and related parameters predicted metabolic syndrome in nigerians. Metab Syndr Relat Disord. 2021; Mar19(2):76–82. PubMed PMID: 33170086; doi: 10.1089/met.2020.0092.
   PubMed Web of Science ®Google Scholar
• Buzova D, Maugeri A, Liguori A, et al. Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD). Clin Epigenetics. 2020; Aug 2012(1):126. doi: 10.1186/s13148-020-00917-2.
   PubMed Web of Science ®Google Scholar
• Guo W, Lu J, Qin P, et al. The triglyceride-glucose index is associated with the severity of hepatic steatosis and the presence of liver fibrosis in non-alcoholic fatty liver disease: a cross-sectional study in chinese adults. Lipids Health Dis. 2020; Oct 719(1):218. doi: 10.1186/s12944-020-01393-6.
   PubMed Web of Science ®Google Scholar
• Smiderle CA, Coral GP, DE Carli LA, et al. Performace of triglyceride-glucose index on diagnosis and staging of nafld in obese patients. Arq Gastroenterol. 2021; Apr-Jun58(2):139–144. doi: 10.1590/s0004-2803.202100000-24.
   PubMedGoogle Scholar
• Khamseh ME, Malek M, Abbasi R, et al. Triglyceride glucose index and related parameters (triglyceride glucose-Body mass index and triglyceride glucose-waist circumference) identify nonalcoholic fatty liver and liver fibrosis in individuals with overweight/obesity. Metab Syndr Relat Disord. 2021; Apr19(3):167–173. doi: 10.1089/met.2020.0109.
   PubMed Web of Science ®Google Scholar
• Huang R, Cheng Z, Jin X, et al. Usefulness of four surrogate indexes of insulin resistance in Middle-aged population in hefei, China. Ann Med. 2022; Dec54(1):622–632. doi: 10.1080/07853890.2022.2039956.
   PubMed Web of Science ®Google Scholar
• Du T, Yuan G, Zhang M, et al. Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance. Cardiovasc Diabetol. 2014; Oct 2013(1):146. doi: 10.1186/s12933-014-0146-3.
   PubMed Web of Science ®Google Scholar
• Yin XY, Zheng FP, Zhou JQ, et al. Central obesity and metabolic risk factors in Middle-aged chinese. Biomed Environ Sci. 2014; May27(5):343–352. doi: 10.3967/bes2014.059.
   PubMed Web of Science ®Google Scholar
• Duan SJ, Ren ZY, Zheng T, et al. Atherogenic index of plasma combined with waist circumference and body mass index to predict metabolic-associated fatty liver disease. World J Gastroenterol. 2022; Sep 2828(36):5364–5379. doi: 10.3748/wjg.v28.i36.5364.
   PubMed Web of Science ®Google Scholar
• Boutari C, Mantzoros CS. Adiponectin and leptin in the diagnosis and therapy of NAFLD. Metabolism. 2020; Feb103:154028. doi: 10.1016/j.metabol.2019.154028.
   PubMed Web of Science ®Google Scholar
• Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012; Feb 1482(7384):179–185. doi: 10.1038/nature10809.
   PubMed Web of Science ®Google Scholar